Bioadaptives (BDPT) Equity Average (2013 - 2026)

Bioadaptives has disclosed Equity Average across 13 years of filings, most recently posting -$2.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at -$2.1 million, down 40.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 40.57% YoY), and the FY2025 annual result was -$1.8 million, down 15.54% from the prior year.
• Equity Average came in at -$2.1 million for Q1 2026 at Bioadaptives, down from -$1.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$1.2 million in Q1 2022 to a low of -$2.1 million in Q1 2026.
• The 5-year median for Equity Average is -$1.5 million (2023), against an average of -$1.6 million.
• Across the five-year window, Equity Average grew 26.59% in 2025 and sank 40.57% in 2026, its largest moves.
• Bioadaptives' Equity Average stood at -$1.5 million in 2022, then grew by 8.36% to -$1.4 million in 2023, then fell by 17.07% to -$1.6 million in 2024, then fell by 9.97% to -$1.8 million in 2025, then fell by 18.66% to -$2.1 million in 2026.
• The last three Equity Average figures came in at -$2.1 million (Q1 2026), -$1.8 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.